ALGS FY 2024 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-74.6% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$89M-2259.9% margin

Net Income

-$131M-3326.0% margin

EPS (Diluted)

$-20.94

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$81M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$70M

Total Liabilities

$99M

Stockholders' Equity

-$29M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$16M	-74.6%
Gross Profit	$4M	$16M	-74.6%
Operating Income	-$89M	-$88M	-1.2%
Net Income	-$131M	-$88M	-49.6%